Consumers and health professionals in Australia are advised that the Therapeutic Goods Administration (TGA) has completed a review of idelalisib and the medicine should no longer be used in combination with rituximab in specific situations outlined in further detail below.
Idelalisib, which is marketed by US biotech major Gilead Sciences (Nasdaq: GILD( as Zydelig, belongs to a group of medicines called antineoplastic agents. It is approved to treat some rare kinds of blood cancer by affecting the growth of cancerous lymphocytes (a type of white blood cell).
This adds to previous safety reviews from drug regulators such as Health Canada and the European Medicines Agency.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze